{"nctId":"NCT02163824","briefTitle":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation","startDateStruct":{"date":"2014-05"},"conditions":["Ocular Infections, Irritations and Inflammations"],"count":380,"armGroups":[{"label":"KPI-121 0.25% QID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: KPI-121 0.25%"]},{"label":"KPI-121 1.0% BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: KPI-121 1.0%"]},{"label":"Vehicle of KPI-121 0.25%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of KPI-121 0.25%"]},{"label":"Vehicle of KPI-121 1.0%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of KPI-121 1.0%"]}],"interventions":[{"name":"KPI-121 0.25%","otherNames":["KPI-121 0.25% Ophthalmic Suspension","Loteprednol etabonate 0.25%"]},{"name":"KPI-121 1.0%","otherNames":["KPI-121 1.0% Ophthalmic Suspension","Loteprednol etabonate 1.0%"]},{"name":"Vehicle of KPI-121 0.25%","otherNames":["Vehicle of KPI-121 0.25% Ophthalmic Suspension"]},{"name":"Vehicle of KPI-121 1.0%","otherNames":["Vehicle of KPI-121 1.0% Ophthalmic Suspension"]}],"eligibilityModule":{"eligibilityCriteria":"FURTHER STUDY DETAILS PROVIDED BY KALA PHARMACEUTICALS, INC.\n\nInclusion Criteria:\n\n* Candidates for routine, uncomplicated cataract surgery\n* In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of at least 20/200 in study eye.\n\nExclusion Criteria:\n\n* Known hypersensitivity/contraindication to study product(s) or components.\n* History of glaucoma, IOP \\>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.\n* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening or 19 days following surgery.\n* In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Resolution of Anterior Chamber Cells","description":"Subjects with complete resolution of anterior chamber cells (cell score = 0) without rescue medication at Day 8/Visit 5 and Day 15/Visit 6.\n\n0= No cells seen\n\n1. 1 to 5 cells\n2. 6 to 15 cells\n3. 16 to 30 cells\n4. greater than 30 cells","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"PRIMARY","title":"Resolution of Ocular Pain","description":"Subjects with complete resolution of pain (grade = 0) without rescue medication at Day 8/Visit 5 and Day 15/Visit 6.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Anterior Chamber Cell Grade at Visit 5.","description":"Mean Grade of Anterior Chamber Cells (Scale 0-4) at Visit 5/Day 8. The difference in mean grade of AC cell count grade at Day 8 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Cells 0 = No cells seen\n\n1. 1 - 5 cells\n2. 6 - 15 cells\n3. 16 - 30 cells 4 = greater than 30 cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.73"},{"groupId":"OG001","value":"0.9","spread":"0.74"},{"groupId":"OG002","value":"1.0","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Anterior Chamber Cell Grade at Visit 6.","description":"Mean Grade of Anterior Chamber Cells (Scale 0-4) at Visit 6/Day 15. The difference in mean grade of AC cell count grade at Day 15 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Cells 0 = No cells seen\n\n1. 1 - 5 cells\n2. 6 - 15 cells\n3. 16 - 30 cells 4 = greater than 30 cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":".65"},{"groupId":"OG001","value":"0.5","spread":".69"},{"groupId":"OG002","value":"0.6","spread":".75"}]}]}]},{"type":"SECONDARY","title":"Ocular Pain Grades at Day 8.","description":"Mean Grade of Ocular Pain (Scale 0-5) at Visit 5/Day 8. The difference in mean grade of ocular pain grade at Day 8 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain. Higher scores were worse outcomes.\n\nThe following scoring scale was used for ocular pain:\n\n0 = None\n\n1. Minimal\n2. Mild\n3. Moderate\n4. Moderately Severe\n5. Severe","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.74"},{"groupId":"OG001","value":"0.4","spread":"0.64"},{"groupId":"OG002","value":"0.5","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Ocular Pain Grades at Day 15.","description":"Mean Grade of Ocular Pain (Scale 0-5) at Visit 6/Day 15. The difference in mean grade of ocular pain grade at Day 15 for KPI-121 1% dosed twice daily (BID) or 0.25% dosed four times daily (QID) compared with vehicle (either dosed BID or QID). Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain.\n\nHigher scores were worse outcomes.\n\nThe following scoring scale was used for ocular pain:\n\n0 = None\n\n1. Minimal\n2. Mild\n3. Moderate\n4. Moderately Severe\n5. Severe","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.50"},{"groupId":"OG001","value":"0.2","spread":"0.51"},{"groupId":"OG002","value":"0.3","spread":"0.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["eye pain","photophobia","eye inflammation","headache","corneal oedema"]}}}